Gilead Sciences Announces Topline Results From Phase 3 TROPiCS-04 Study In Metastatic Urothelial Cancer; Trodelvy Fails To Meet Primary Endpoint Of Overall Survival
Portfolio Pulse from Benzinga Newsdesk
Gilead Sciences announced that its Phase 3 TROPiCS-04 study for Trodelvy in metastatic urothelial cancer did not meet its primary endpoint of overall survival.
May 30, 2024 | 8:45 pm
News sentiment analysis
Sort by:
Ascending
NEGATIVE IMPACT
Gilead Sciences' Phase 3 TROPiCS-04 study for Trodelvy in metastatic urothelial cancer did not meet its primary endpoint of overall survival, which could negatively impact investor sentiment and short-term stock price.
The failure to meet the primary endpoint in a Phase 3 study is a significant setback for any pharmaceutical company. This news is likely to negatively impact Gilead Sciences' stock price in the short term as it may affect investor confidence in the company's oncology pipeline.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100